Phase 2 Trial Begins for Early Alzheimer’s with Sinaptica’s Neuromodulation System

Phase 2 Trial Begins for Early Alzheimer’s with Sinaptica’s Neuromodulation System Sinaptica Therapeutics, Inc., a clinical-stage company focused on developing personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the launch of a Phase 2 clinical trial for…